12:00 AM
Apr 23, 2007
 |  BioCentury  |  Product Development

The neurology of GERD

Inhibiting metabotropic glutamate receptor subtype 5 could have utility in indications as different as gastroesophageal reflux disease and migraine. Addex Pharmaceuticals S.A. last week said its allosteric inhibitor of mGluR5 is the first product in the class to show clinical signs of efficacy in both indications.

The link between GERD and migraine is the location of mGluR5 receptors at key points in the signaling pathways involved in both pathologies(see BioCentury, Sept. 11, 2006). Working through the neural network is a new approach in GERD that may provide relief to patients for whom acid reduction is not enough.

Tightening up in GERD

Marketed products to treat GERD work by reducing stomach acidity, but Addex thinks ADX10059 may address the real etiology of the disease: inappropriate sphincter relaxation.

"This is the first demonstration that this mechanism of action plays a role in this pathology and can have therapeutic value," said Vincent Mutel, CEO...

Read the full 741 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >